Alder BioPharmaceuticals is bringing new therapies to the treatment of migraine, autoimmune and inflammatory diseases, and other conditions.

 

Newswire

Alder BioPharmaceuticals to Present at 26th Annual Piper Jaffray Healthcare
Conference> Read the story
Data From Phase 2b Clinical Trial of Clazakizumab, an Anti-IL-6 Monoclonal Antibody for the Treatment of Active Psoriatic Arthritis, to be Presented at the American College of Rheumatology Annual Meeting> Read the story

Trendlines

Fact

Migraine is a significant cause of disability, generally affecting individuals between the ages of 20 and 50, their prime working years.
The Migraine Research Foundation estimates U.S. employers lose more than US$13 billion each year as a result of 113 million lost workdays due to migraine.
For the 12.6 million U.S. migraine patients who are candidates for migraine prevention, there are few therapeutic options to manage their disease.
According to a 2012 report by the U.S. Agency for Healthcare Research and Quality, headaches accounted for 2.1 million visits to the emergency room annually.
According to the American Migraine Foundation, migraine is three times more common in women than men and migraine affects 30% of women over a lifetime.
ALD403 is a monoclonal antibody, discovered by Alder, which targets CGRP for prevention of migraine. CGRP is a small protein that is involved in the transmission and heightened sensitivity to pain experienced in migraine.
Rheumatoid arthritis is a chronic inflammatory disorder that principally attacks joints. Approximately 2.4 million patients, predominantly women, suffer from RA in the United States.
Clazakizumab is a humanized monoclonal antibody, discovered by Alder, which binds to and inhibits IL-6. IL-6 is an important driver of the inflammatory response and is implicated in the transition from acute to chronic inflammation.
Approximately 36 million Americans suffer from migraines, but only 20 million migraine sufferers have been clinically diagnosed.